medigraphic.com
ISSN 2992-8559 (Electronic)
ISSN 1405-0625 (Print)

2002, Number 2

<< Back Next >>

Cir Plast 2002; 12 (2)

The utility of the botulinum toxin as an aid in the treatment of spastic palsy in the upper limbs of patients with infant cerebral palsy

Ramírez LEA, Álvarez-Díaz CJ, Maldonado JG, Núñez OMA

Language: Spanish
References: 19
Page: 57-60
PDF size: 44.04 Kb.


ABSTRACT

A group of 22 children with an average of 9 years bearing sequels of infantile cerebral palsy, were injected in the spastic muscular units with a type A botulinum toxin (Botox: Allergan) at a dose of 1 to 2 U/kg of corporal weight, without exceeding 100 U. The range of movement of the joints was measured according to the Ashword criteria, before and after the application of the toxin, with good results in up to six months of follow-up, without adverse reactions. It is concluded that the type A botulinum toxin has an application in this type of patients.


REFERENCES

  1. Brin MF. Botulinum Toxin: Chemistry, Pharmacology, Toxicity, and Immunology. Muscle Nerve 1997; 0 (Suppl 6): S146-S168.

  2. Pearce LB. Pharmacologic Characterization of Botulinum Toxin for Basic science and Medicine. Toxicon 1997; 35: 1373-412.

  3. Tugnoli V. The therapeutic use of botulinum toxin. Exp Opin Invest Drugs 1997; 6(10): 1383-94.

  4. Fehlin D. An evaluation of botulinum-A-toxins to improve upper extremity in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331-7.

  5. Aoki R. Botox Purified Neurotoxin Complex Prepared from the New Bulk Toxin Retains Same Preclinical Efficacy as the Original but Reduced Immunogenicity. Neurology 1999; 12 52(6Suppl2): A521-P06.109.

  6. Cox NH. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol 1999; 40: 263-264.

  7. Calderon R. Botulinum Toxin A in Management of Cerebral Palsy. Pediatr Neurol 1994; 10: 284-288.

  8. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.

  9. Deaver GG, Brown ME. Physical Demands of daily life New York Institute for the crippled and disabled 1945.

  10. Santa Fe MM. Calcium channels involved in transmitter release in Botulinum toxin treated neuromuscular junction. J Neurol Sci 1997; 150: S255.

  11. Klein AW. Treatment of facial Furrows and Rhytides. Dermatol Clin 1997; 15: 595-607.

  12. Sanchez Carpintero R. Botulin Toxin in spastic infantile cerebral palsy: results in 27 cases during one year. J Rev Neurol 1997; 25: 531-5.

  13. Gordon N. The role of botulinum toxin type A in treatment—with special reference to children. Brain Dev 1999; 21: 147-51.

  14. Pribikin EA. Patient Selection in treatment of Glabellar Wrinkles with Botulinum Toxin Type A Injection. Arch Otolaryngol Head Neck Surg 1997; 123: 321-6.

  15. Massin M. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 1999; 19: 362-5.

  16. Mall V. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil 1997; 1: 235-7.

  17. Friedman A. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000; 79: 53-9; quiz 75-6.

  18. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 1998; 18: 124-31.

  19. Pascual-Pascual SI. Botulinum toxin as a treatment for infantile cerebral palsy. Rev Neurol 1997; 25: 1369-75.




2020     |     www.medigraphic.com